Sirvi Autor "Kisand, Kalle" järgi

Nüüd näidatakse 1 - 2 2

Demographic associations for autoantibodies in disease-free individuals of a European population
(2016) Haller-Kikkatalo, Kadri; Alnek, Kristi; Metspalu, Andres; Mihailov, Evelin; Metsküla, Kaja; Kisand, Kalle; Pisarev, Heti; Salumets, Andres; Uibo, Raivo
The presence of autoantibodies usually precedes autoimmune disease, but is sometimes considered an incidental finding with no clinical relevance. The prevalence of immune-mediated diseases was studied in a group of individuals from the Estonian Genome Project (n = 51,862), and 6 clinically significant autoantibodies were detected in a subgroup of 994 (auto)immune-mediated disease-free individuals. The overall prevalence of individuals with immune-mediated diseases in the primary cohort was 30.1%. Similarly, 23.6% of the participants in the disease-free subgroup were seropositive for at least one autoantibody. Several phenotypic parameters were associated with autoantibodies. The results suggest that (i) immune-mediated diseases are diagnosed in nearly one-third of a random European population, (ii) 6 common autoantibodies are detectable in almost one-third of individuals without diagnosed autoimmune diseases, (iii) tissue non-specific autoantibodies, especially at high levels, may reflect preclinical disease in symptom-free individuals, and (iv) the incidental positivity of anti-TPO in men with positive familial anamnesis of maternal autoimmune disease deserves further medical attention. These results encourage physicians to evaluate autoantibodies in addition to treating a variety of patient health complaints to detect autoimmune-mediated disease early.
Immunoloogia
(Tartu Ülikooli Kirjastus, 2024-11-28) Uibo, Raivo; Kisand, Kalle; Peterson, Pärt; Reimand, Koit
Käesolev eestikeelne immunoloogiaõpik on tänapäevastatud versioon 2015. a ilmunud õpikust. Uue õpikuteksti kirjutamise vajaduse tingis immunoloogiateaduse ja selle meditsiiniliste rakendusvõimaluste kiire areng viimastel aastatel. Seetõttu sai autoritele oluliseks küsimuseks, mida uues versioonis kajastada ja mida mitte. Arusaadavalt on need valikud rasked, eriti kui arvestada neid mitmekesiseid teadmisi, mida on saadud uute nakkushaiguste (COVID-19 jt) immuunmehhanismide uuringutes. Kiiresti on suurenenud ka immunoregulatoorsete protsesside teaduslike andmete hulk. Tänu immuunsüsteemi kontrollpunktide mõjutamisel saadud kliiniliste uuringute tulemustele on avanenud uued võimalused kasvajate raviks. Näiteid viimase ligemale kümne aasta saavutustest immunoloogias võib tuua rohkelt ning seda kõike püüdsid autorid uues õpikuversioonis ka tasakaalustatult kajastada. Käesolevas väljaandes on mitmeid uusi jooniseid, tabeleid jm, mis peaksid lugemist hõlbustama.